Date: 2013-02-20
Type of information: Development agreement
Compound: Shigamabs® program
Company: LFB Biotechnologies, Laboratoire français du fractionnement des biotechnologies (France) Thallion Pharmaceuticals (Canada)
Therapeutic area: Infectious diseases
Type agreement: development
licensing
Action mechanism: Shigamabs® consists of two monoclonal antibodies designed to bind specifically and exclusively to the Shiga toxin 1 and Shiga toxin 2 toxins secreted by Shiga toxin- producing E. coli bacteria. STEC infections are primarily foodborne bacterial infections that cause serious health complications, particularly in young children and the elderly, and affect approximately 314,000 people annually in the industrialized world. There are no approved products available for the treatment of STEC infections. The Shigamabs® antibodies, administered as a single intravenous infusion, bind to their respective toxin and neutralize them by forming a complex that is absorbed and destroyed by the liver and spleen. The dual antibody approach enables Shigamabs® to address STEC infections caused by E. coli secreting either Shiga toxin 1, Shiga toxin 2 or both Shiga toxins. Shigamabs® has obtained orphan drug designation both in the U.S. and in Europe.
Disease:
Details: * On February 20, 2013, Thallion Pharmaceuticals and LFB Biotechnologies have announced that they have reached an agreement on the termination of their development and licensing agreement related to Thallion\'s Shigamabs® program. All rights to the program will revert back to Thallion including all data, materials and know-how developed by and for LFB during the collaboration. LFB will cease to have any rights to the Shigamabs® program and all future quarterly payments due to Thallion by LFB in support of Shigamabs® development will terminate. LFB will pay for all outstanding and accrued costs related to product manufacturing and Thallion will be responsible for all remaining costs associated with the completion of the SHIGATEC Phase II clinical study.
\"Thallion has been an excellent partner in this program and Shigamabs® could be an important product for alleviating the suffering of the thousands of patients infected by STEC each year,\" said Guillaume Bologna, executive VP of LFB Biotechnologies for development & business development. \"Despite our strong collaboration, an internal pipeline prioritization necessitated a reallocation of our resources. We wish Thallion much success in the future.\"
Financial terms:
Latest news:
